Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Breaking News: Top 10 Headlines From The Week

Mar 17, 2017 • 12:04 PM EDT
THE NEW YOU (2).png
5 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

The Cannabis Industry will end the week up as whole via The Marijuana Index. To recap the week, here are 10 of the catalysts that helped propel the sector:

Insys Therapeutics (INSY) will delay the release of its fourth quarter and full year financial results.  The company’s audit committee has been conducting an independent review of processes related to estimation of, and increases to, certain sales allowances recorded in 2016. The audit may result in lower net revenue and pre-tax income during 2015 (no more than $5 million). The committee will also review the extended payment terms offered to certain customers in the third quarter of 2016.

Vinergy Resources (VIN.CN) (VNNYF) reported the development of a disruptive solvent based extraction system. The project is currently underway for an existing customer and is focused on improving the purity of medical products. The company plans to provide more information regarding this system in the coming weeks.

Zoned Properties, Inc. (ZDPY) completed the sale of one of its properties located in Tempe, Arizona. ZDPY sold the property for $2.125 million. The land was leased to a non-marijuana business, and management viewed it as non-core to its strategy.

MassRoots, Inc. (MSRT) retired all convertible debt on its balance sheet and has received substantial warrant exercises so far this year. This has significantly improved its capitalization table and cash position. According to a non-objecting beneficial owners report, MassRoots has more than 20,000 shareholders and only one shareholder with more than 5% of outstanding shares. 

Innovative Industrial Properties (IIPR) will report its fourth quarter financial results on March 22nd (after the market closes). The results will be for the period that started on June 15th (the date of incorporation) and ended on December 31st.

Veritas Pharma Inc. (VRT.CN: CSE) (VRTHF: OTC) announced that its research arm, Cannevert Therapeutics will soon be in the security inspection stage of its Health Canada Dealer’s License application. Cannevert submitted its application to Health Canada’s Office of Controlled Substances on August 23, 2016.

Organigram Holdings Inc. (OGI.V) (OGRMF), recorded single-week sales of over $250,000 for the first time in its history for the period March 5-11, 2017. The record-setting sales follow the release of Organigram’s newly harvested and tested marijuana. The crops were grown under the company’s new operating protocols which includes testing all harvested product to ensure the product’s purity.  Following the recalls, Organigram implemented seven new company-wide initiatives to ensure product quality.

Future Farm’s (FFT.CN: CSE) (FFRMF) majority owned subsidiary, FFM Consulting Services entered a management agreement with a California non-profit company that secured a sublease to grow cannabis in Riverside County, California. The cannabis will be sent to the previously announced extraction facility and it will be further processed into cannabis concentrates.

mCig (MCIG) has been under pressures since it reported its financial and operating results for the period that ended on January 31st. Although we are not buyers at current levels, we want to highlight some of the bright spots of the report to highlight how this company has turned things around over the last year.w
Financial and Liquidity Highlights

  • Revenue was $1,362,689 (accounts receivable $520,454)
  • Gross profit was $288,230 (21.1% gross margin)
  • Total operating expenses were $97,052
  • Net income of $850,552
  • Avg. Shares Outstanding (basic & diluted) increased by 41.4+ million
  • Cash and cash equivalents as of 1/31 was $420,488
  • Current assets were $1.25+ million
  • Current liabilities were $287,712

Lexaria Bioscience Corp. (LXRP) reported $82,832.91 from the exercise of stock options and warrants that were previously granted. The stock options were exercised at the price of $0.2273, and the warrants were exercised at prices of $0.14 to $0.2273 (465,000 shares issued). All warrants and options that were exercised were done by third parties who are neither officers nor directors of the company.

Have these insights and much more delivered daily to your inbox by signings up for Mushroomstocks HERE. 


Important Investor Disclosures

Disclosure.  Compensated Affiliate.  This report was authored by and is property of StoneBridge Partners LLC.  All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional adviceregarding any and all securities investments.  This report is intended for informational purposes only.  StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC.  StoneBridge Partners LLC receives 

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.